Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387:132–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;390:301–13.

Article  CAS  PubMed  Google Scholar 

Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. (2023). https://doi.org/10.1016/S2352-3026(23)00236-3.

Jakubowiak A, Usmani SZ, Krishnan A, Lonial S, Comenzo RL, Wang J, et al. Daratumumab plus carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk. 2021;21:701–10.

Article  CAS  PubMed  Google Scholar 

Landgren O, Hultcrantz M, Diamond B, Lesokhin AM, Mailankody S, Hassoun H, et al. Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial. JAMA Oncol. 2021;7:862–8.

Article  PubMed  PubMed Central  Google Scholar 

Barnidge D, Troske D, North S, Wallis G, Perkins M, Harding S. Endogenous monoclonal immunoglobulins analyzed using the EXENT® solution and LC-MS. J Mass Spectrom Adv Clin Lab. 2024;32:31–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e346.

Article  PubMed  Google Scholar 

Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, et al. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021;35:18–30.

Article  PubMed  Google Scholar 

Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1:710–9.

Article  CAS  PubMed  Google Scholar 

Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021;22:1705–20.

Article  CAS  PubMed  Google Scholar 

Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120:1801–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21:1317–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kazandjian D, Korde N, Mailankody S, Hill E, Figg WD, Roschewski M, et al. Remission and progression-free survival in patients with newly diagnosed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone: five-year follow-up of a phase 2 clinical trial. JAMA Oncol. 2018;4:1781–3.

Article  PubMed  PubMed Central  Google Scholar 

Derman BA, Kansagra A, Zonder J, Stefka AT, Grinblatt DL, Anderson LD Jr, et al. Elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma without transplant intent: a phase 2 measurable residual disease–adapted study. JAMA Oncol. 2022;8:1278–86.

Article  PubMed  PubMed Central  Google Scholar 

Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. (2023). https://doi.org/10.1016/S2352-3026(23)00217-X.

Mateos M-V, San-Miguel J, Cavo M, Bladé Creixenti J, Suzuki K, Jakubowiak A, et al. Daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 alcyone study. Blood. 2022;140:10157–9.

Article  Google Scholar 

Avet Loiseau H, Sonneveld P, Moreau P, Offner F, van der Velden VHJ, Caillot D, et al. Daratumumab (DARA) with bortezomib, thalidomide, and dexamethasone (VTd) in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (NDMM): analysis of minimal residual disease (MRD) negativity in cassiopeia part 1 and part 2. Blood. 2021;138:82.

Article  Google Scholar 

Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. JCO. (2021). https://doi.org/10.1200/JCO.21.01935.

Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 2022;9:e810–e21.

Article  CAS  PubMed  Google Scholar 

Leypoldt LB, Tichy D, Besemer B, Hänel M, Raab MS, Mann C, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. JCO. (2023). https://doi.org/10.1200/JCO.23.01696.

Gay F, Roeloffzen W, Dimopoulos MA, Rosiñol L, van der Klift M, Mina R, et al. Results of the phase III randomized iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. Blood. 2023;142:4.

Article  Google Scholar 

Knop S, Stuebig T, Kull M, Greil R, Steiner N, Bassermann F, et al. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study. JCO. 2023;41:8000.

Article  Google Scholar 

Callander N, Silbermann R, Kaufman JL, Godby KN, Laubach JP, Schmidt TM, et al. Analysis of transplant-eligible patients (Pts) who received frontline daratumumab (DARA)-based quadruplet therapy for the treatment of newly diagnosed multiple myeloma (NDMM) with High-risk Cytogenetic Abnormalities (HRCA) in the griffin and master studies. Blood. 2022;140:10144–7.

Article  Google Scholar 

Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, et al. Outcomes of autologous stem cell transplant in patients with ultra high-risk multiple myeloma. Transplantat Cell Ther. (2023). https://doi.org/10.1016/j.jtct.2023.08.031.

Kaiser MF, Hall A, Walker K, Sherborne A, De Tute RM, Newnham N, et al. Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma. JCO. (2023). https://doi.org/10.1200/JCO.22.02567.

Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jasielec J, Kubicki T, Raje N, Vij R, Reece D, Berdeja JG, et al. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. (2020). https://doi.org/10.1182/blood.2020007522.

Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715–25.

Article  CAS  PubMed  Google Scholar 

Kubicki T, Dytfeld D, Barnidge D, Sakrikar D, Lakos G, Przybylowicz-Chalecka A, et al. Mass spectrometry-based assessment of M-protein in peripheral blood during maintenance therapy in multiple myeloma (MM) in the phase III ATLAS trial. Blood. 2023;142:340.

Article  Google Scholar 

Mateos M-V, Paiva B, Cedena Romero MT, Puig N, Sureda Balari AM, Oriol A, et al. GEM2017FIT trial: induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus/minus daratumumab (D), 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: phase iii, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma (NDMM) patients aged between 65 and 80 years. Blood. 2023;142:209.

Article  Google Scholar 

Chakraborty R, Hamilton BK, Hashmi SK, Kumar SK, Majhail NS. Health-related quality of life after autologous stem cell transplantation for multiple myeloma. Biol Blood Marrow Transpl. 2018;24:1546–53.

Article  Google Scholar 

Rosenberg AS, Brunson A, Tuscano J, Jonas BA, Hoeg R, Wun T, et al. Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. Blood Cancer J. 2021;11:1–11.

Article  Google Scholar